Login
ARVINAS, INC. logo

ARVINAS, INC.

arvinas.com

What Do They Do?

Develops protein-degrading drug candidates for people with cancer and neurodegenerative diseases.

How Do They Make Money?

Pharmaceutical partners pay Arvinas under research and licensing agreements, which can include upfront fees and research payments; revenue from the combined work is earned over the agreement period. Agreements may also bring milestone payments and royalties when customer product sales occur.

FY2025 revenue

Who Are Their Customers?

Arvinas works with pharmaceutical partners such as Pfizer and Genentech through research and licensing collaborations.

Do Revenues Turn Into Profits?

No. It lost $80.8M in FY2025.

Operating income, FY2025
−45% of revenue
▲ +53% (Loss) vs FY2024 (−$250.2M, −95%)
Net income, FY2025
−31% of revenue
▲ +59% (Loss) vs FY2024 (−$198.9M, −76%)
Free cash flow, FY2025
−105% of revenue
▼ −6% (Loss) vs FY2024 (−$261.1M, −99%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −99%
vs $41.9M in Q3 FY2025
Net income
▼ −54% (Loss)
vs −$35.1M in Q3 FY2025
  • Aug 4, 2026 VEPPANU received FDA approval and its rights were licensed to Rigel Rigel received exclusive global development, manufacturing and commercialization rights for VEPPANU.
  • Jun 16, 2026 Rigel's VEPPANU license took effect Rigel paid a $70.0 million upfront amount to Arvinas and Pfizer collectively; future milestone payments and royalties are also possible.

Growing. Revenue grew 4.9x in 4 years, from $53.6M in FY2021 to $262.6M in FY2025, about 49% a year.

Broader focus on neurology The older report centered its clinical drug candidates on breast and prostate cancers; the latest report also describes candidates for neurodegenerative diseases such as Parkinson’s disease.

Who Do They Compete With?

Competes with Accutar Biotechnology, C4 Therapeutics, Cullgen, Foghorn Therapeutics, Kymera Therapeutics, Nurix Therapeutics, Proteovant Therapeutics, AbbVie, Amgen, Astellas Pharma, AstraZeneca, BeOne Medicines, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Genentech, Novartis, Pfizer, Sanofi, and IONIS Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support